Clinical Trials List
2023-05-01 - 2027-05-31
Phase III
Not yet recruiting9
Recruiting2
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
-
Trial Applicant
GILEAD SCIENCES HONG KONG LIMITED
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/13
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- HWEI-CHUNG WANG 無
- 黃至豪 無
- Chih-Jung Chen 無
- Chen-Teng Wu 無
- Yao-Chung Wu 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Shang-Hung Chen 無
- Zhu-Jun Loh 無
- Kuo-Ting Lee 無
- Wei-Pang Chung 無
- Yao-Lung Kuo 未分科
- 楊舜如 無
- Chun-Hui Lee 無
- Jui-Hung Tsai 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 何蕙余 無
- 周旭桓 無
- Chi-Chang Yu 無
- 阮昱翔 無
- Mengting Peng 無
- 沈士哲 無
- Yung-Chang Lin 無
- Chan-Keng Yang 無
- Wen-Chi Shen 無
- Shin-Cheh Chen 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Shau-Hsuan Li 無
- 郭明濬 無
- Yu-Li Su 無
- 吳佳哲 無
- Tai-Jan Chiu 無
- 黃詩喻 無
- 李易濰 無
- 陳彥仰 無
- 林昶廷 無
- 陳彥豪 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 蔡郁棻 無
- 洪朝明 無
- Meng-Jer Hsieh 無
- 李蕙鳴 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
39 participants
-
Global
540 participants
